跳至主要内容
临床试验/NCT04253405
NCT04253405终止不适用

Multicentric Randomized Controlled Pilot Study Comparing High Flow Nasal Cannula Versus NonInvasive Positive Pressure Ventilation in Acute Respiratory Failure in Patients With Pulmonary Fibrosis (RENOVATE Fibrosis)

Hospital do Coracao6 个研究点 分布在 1 个国家目标入组 3 人开始时间: 2020年12月10日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
3
试验地点
6
主要终点
Recruitment feasibility

研究概览

简要总结

A pilot multicentric randomized controlled study investigating the feasibility of recruiting 50 pulmonary fibrosis patients in acute respiratory failure within18 months. Additionally, exploratory efficacy and safety outcomes will be evaluated.

详细描述

RENOVATE Fibrosis will recruit patients with pulmonary fibrosis in acute respiratory failure to be randomized to HFNC or NIPPV. Efficacy and safety outcomes measured are dyspnea variation, physiological variables (pCO2, respiratory rate, oxygenation), comfort, endotraqueal intubation rate, mortality in 28 and 90 days.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Sequential adult patients 18 years of age or older admitted to the hospital with pulmonary fibrosis and acute onset of respiratory failure that meets criteria A and B bellow.
  • A. Pulmonary fibrosis will be defined by all of the criteria below:
  • presence of Velcro-type crackles on physical examination
  • imaging compatible with pulmonary fibrosis
  • diffuse disease on imaging
  • B. Acute respiratory failure (ARF) will be defined by hypoxemia evidenced by SpO2 <90% or PaO2 <60 mmHg in room air and at least two of the criteria below within the last four weeks:
  • worsening dyspnea
  • worsening breathing effort
  • worsening gas exchange (worsening SpO2 or paO2)
  • worsening respiratory rate, above 25 irpm

排除标准

  • Pulmonary fibrosis secondary to progressive massive fibrosis (silicosis), or any other tumor form of fibrosis;
  • Significant pulmonary arterial hypertension characterized by: Right ventricular failure on Doppler echocardiogram or Cardiac index <2L / min / m2 in catheterization of right chambers;
  • Pneumothorax or extensive pleural effusion as the main determinant of ARF in the assessment of the attending physician;
  • Cardiogenic pulmonary congestion as the main determinant of IRPA in the assessment of the attending physician;
  • Presence of delirium or non-cooperation at the time of randomization;
  • Anatomical facial abnormalities;
  • Incoercible vomiting or hypersecretion of the airways;
  • Use of continuous VNIPP or HFNC for more than 8h before randomization;
  • pregnancy;
  • Refusal to participate.

结局指标

主要结局

Recruitment feasibility

时间窗: 18 months

Recruitment of 50 pulmonary fibrosis patients in acute respiratory failure in 18 months

次要结局

  • Dyspneia variation (Borg scale)(7 days)
  • Respiratory frequency variation(7 days)
  • oxygen saturation/fraction of inspired oxygen (SpO2/FiO2) variation(7 days)
  • Carbon dioxide arterial partial pressure (PaCO2) variation(7 days)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (6)

Loading locations...

相似试验